Midwife Maven
Want to know what that brain fog is telling you?
Your Brain in Perimenopause: What the Fog Is Actually Telling You.
The cognitive changes of perimenopause are real, measurable, and rooted in biology. They are also almost never what women fear they are.
Most women I speak with who are in perimenopause have already diagnosed themselves. They call it brain fog. They describe walking into a room and forgetting why. Words that used to come easily now stall somewhere between thought and speech. And then, almost universally, they say something that concerns me more than any of those symptoms: they wonder if they are losing their mind.
They are not. What they are experiencing is real, measurable in research settings, and directly tied to the hormonal biology of the perimenopause transition. In the large majority of cases, it is also temporary.
What the research actually shows
The Study of Women’s Health Across the Nation (SWAN) tracked cognitive performance in 2,362 perimenopausal women over four years across processing speed, verbal episodic memory, and working memory. The finding was striking not for its severity but for its precision.
Perimenopausal women did not show declining test scores. What happened instead was that they stopped improving. In midlife, it is normal to get better at cognitive tasks each time you practice them — a pattern called the learning effect. Premenopausal and postmenopausal women showed this expected improvement at each annual visit. Perimenopausal women did not. Their scores stayed flat, which in cognitive research represents a meaningful difference from expected performance.
This is not dementia. It is a hormonally mediated, time-limited disruption in how efficiently the brain learns and retrieves information during a period of significant hormonal fluctuation. The SWAN data showed that once women moved into postmenopause and hormone levels stabilized, the learning effect returned.
Roughly 60 percent of women report cognitive difficulties during the menopause transition. Only 11 to 13 percent show what researchers classify as clinically significant impairment. The subjective experience of brain fog is widespread and real. The measured magnitude of cognitive change is typically subtle.
The SWAN finding restated plainly
Perimenopausal women were not getting worse at cognitive tasks. They were failing to get better the way they normally would. Processing speed and verbal memory scores did not decline — they plateaued. Once women moved into postmenopause, the expected improvement with repeated testing resumed. This is important context for women who fear the fog means something more serious than it typically does.
Why estrogen matters to your brain
Estrogen receptors are distributed throughout the central nervous system, with particularly high concentrations in the hippocampus and prefrontal cortex — the regions most directly involved in memory formation, verbal learning, working memory, and executive function. The same regions most implicated in perimenopausal cognitive symptoms are the same regions most dependent on estrogen signaling.
Estrogen supports synaptic plasticity, regulates neurotransmitter activity (acetylcholine, serotonin, dopamine), maintains cerebral blood flow and blood-brain barrier integrity, supports mitochondrial function and glucose utilization in neurons, and has direct antioxidant and neuroprotective effects. When estrogen declines during perimenopause — and particularly when levels fluctuate unpredictably rather than declining smoothly — each of these systems is affected simultaneously. The brain is maintaining its functional baseline with less hormonal support than it has relied on throughout adulthood. That effort has cognitive costs.
Brain energy and the Alzheimer’s question
One of the less-discussed mechanisms connecting estrogen loss to cognitive change is its effect on brain energy metabolism. The brain accounts for roughly 20 percent of the body’s total energy consumption. That demand is met primarily through glucose metabolism — a process estrogen actively regulates. Brain imaging research has documented that glucose metabolism measurably declines during perimenopause, with reductions in regions particularly vulnerable to Alzheimer’s disease pathology. The gradient is consistent: metabolism is lowest in postmenopausal women, intermediate in perimenopausal women, and closest to normal in premenopausal women — a pattern that reflects menopause stage independently of chronological aging.
Women account for roughly two-thirds of Alzheimer’s disease cases in the United States, a proportion that cannot be explained by longer average lifespan alone. The menopause transition appears to be part of the story.
I want to be careful and precise here. The brain fog most women experience in perimenopause is not an early sign of Alzheimer’s disease. The cognitive changes of the transition are temporary and hormonally mediated, not neurodegenerative. What the research does suggest is that the menopause transition represents a window of vulnerability for the brain — one during which the loss of estrogen’s neuroprotective support coincides with metabolic changes that, over subsequent decades, may influence who develops cognitive decline and when.
What we know and what we don’t
What is established: women have higher lifetime Alzheimer’s risk than men, brain glucose metabolism declines during perimenopause in regions vulnerable to Alzheimer’s pathology, and APOE4 genotype intersects with menopause in ways that affect brain aging. What remains unclear: whether interventions during the perimenopause window meaningfully modify lifetime dementia risk, and which women benefit most from which interventions. This is research worth watching.
Sleep, stress, and why the fog compounds
Brain fog during perimenopause is rarely produced by estrogen changes alone. Sleep deprivation impairs memory consolidation, attention, processing speed, and executive function. The glymphatic system — the brain’s waste-clearance mechanism, active primarily during deep sleep — depends on consistent rest to clear metabolic byproducts including the amyloid and tau proteins implicated in Alzheimer’s pathology. Women experiencing nighttime hot flashes and disrupted sleep are accumulating a cognitive debt with each broken night.
Cortisol rises with both stress and disrupted sleep, and high cortisol over extended periods is associated with hippocampal volume reduction and impaired neurogenesis. The hippocampus is where most verbal memory formation begins. A woman managing poor sleep, elevated stress, and fluctuating estrogen simultaneously is experiencing three independent sources of hippocampal suppression at once.
This is why I think about perimenopausal brain fog as a cluster problem more than a single-hormone problem. Addressing sleep, stress, and vascular health is not tangential to the brain question. It is the brain question.
What actually helps
Aerobic exercise is the most consistently documented brain-protective intervention available. Regular aerobic exercise supports hippocampal neurogenesis, increases BDNF (brain-derived neurotrophic factor), improves cerebral blood flow, reduces neuroinflammation, and is associated with larger hippocampal volume in older adults who exercise compared to sedentary peers. Women who exercise regularly during perimenopause show better cognitive performance on objective testing. This is a meaningful intervention, not merely a general health recommendation.
Sleep quality is next. Treating sleep disruption during perimenopause (through hormone therapy, behavioral strategies, or both) is a direct brain health intervention, not a comfort measure. Vascular risk factors are also directly relevant: blood pressure control, blood sugar regulation, and managing inflammatory markers are among the strongest modifiable predictors of cognitive health later in life.
On hormone therapy: the SWAN data showed that women who initiated hormone use before their final menstrual period scored 4 to 6 percent higher on cognitive tests than those who had not. Women who initiated after their final menstrual period did not show the same benefit. This is consistent with the critical window hypothesis: estrogen’s neuroprotective effects depend substantially on when exposure occurs relative to the transition. Timing matters, and it deserves its own conversation, which is where this series is heading next.
What to hold onto right now
Memory is identity. When it starts feeling unreliable, the fear is not just about forgetting things. It is about who you are and whether you are intact. So here is what I want you to know: the fog is real, it is biological, it is not your fault, and in the large majority of cases it is not permanent.
The interventions that help most (exercise, sleep quality, stress regulation, vascular health) are not compensatory measures. They are the actual biological levers for brain function during this transition.
When you come in to talk about cognitive symptoms, I am not going to dismiss them or tell you they are normal and therefore not worth addressing. They are real. They have a biological explanation. And they are worth taking seriously. That is the conversation we need to be having.
Sources
1. Greendale GA, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009;72(21):1850-1857.
2. Greendale GA, et al. Menopause-associated symptoms and cognitive performance: results from SWAN. American Journal of Epidemiology. 2010;171(11):1214-1224.
3. El Khoudary SR, et al. The menopause transition and women’s health at midlife: a progress report from SWAN. Menopause. 2019;26(10):1213-1227.
4. Weber MT, et al. Cognition in perimenopause: the effect of transition stage. Menopause. 2013;20(5):511-517.
5. Maki PM, et al. Brain fog in menopause: a health-care professional’s guide for decision-making and counseling on cognition. Climacteric. 2022;25(6):570-578.
6. Mosconi L, et al. Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery. PLOS ONE. 2017;12(10):e0185926.
7. Valencia-Olvera AC, et al. Role of estrogen in women’s Alzheimer’s disease risk as modified by APOE. Journal of Neuroendocrinology. 2023;35(2):e13209.
8. Nerattini M, et al. Systematic review and meta-analysis of menopause hormone therapy and the risk of Alzheimer’s disease and all-cause dementia. Frontiers in Aging Neuroscience. 2023;15:1260427.
9. Saleh RNM, et al. Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the EPAD cohort. Alzheimer’s Research and Therapy. 2023;15:10.
10. Frontiers in Molecular Biosciences. Estrogen, menopause, and Alzheimer’s disease: understanding the link to cognitive decline in women. 2025;12:1634302.
11. Erickson KI, et al. Exercise training increases size of hippocampus and improves memory. PNAS. 2011;108(7):3017-3022.
12. El Haj M, et al. Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis. Lancet Healthy Longevity. 2025.
Past articles:
 | A guest post by
|